Annovis Publishes Historical Review of Buntanetap in The Scientist

Core Insights - Annovis Bio, Inc. is advancing its clinical pipeline with the investigational oral therapy, buntanetap, targeting neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1][2] - A recent article published in The Scientist details the history and development of buntanetap, highlighting its journey from discovery to its current Phase 3 clinical trials [2][3] Company Overview - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company based in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases [5] - The lead drug candidate, buntanetap, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism [5] Clinical Development - Buntanetap is currently being evaluated in a pivotal Phase 3 study for early AD, with 70% of patients enrolled, and in an open-label extension study for PD, with 20% of patients enrolled [2] - The article in The Scientist provides context for understanding the scientific journey of buntanetap, including its mechanism of action and the challenges faced during its development [2][3] Scientific Communication - The publication reflects Annovis' commitment to scientific transparency and education as it approaches important clinical and regulatory milestones [3] - The Scientist serves as a trusted platform for communicating advances in biology, medicine, and drug development, catering to life science professionals and researchers [3]